Recent news on Adefovir Dipivoxil

Lamivudine-Resistant Hepatitis B Patients Achieve Sustained ...  -  Apr 17, 2007
DG NewsBARCELONA, SPAIN -- April 17, 2007 -- Long-term treatment with adefovir dipivoxil and lamivudine decreases the risk of genotypical resistance to adefovir in

Adefovir And Lamivudine Combo Is Effective In Lamivudine-Resistant ...  -  Apr 16, 2007
Medical News Today (press release),Long-term treatment with adefovir dipivoxil (ADV, HepseraR) and lamivudine provides multiple benefits in lamivudine-resistant patients with chronic

Gilead's Atripla, Lower Costs Provide Lift To First Quarter  -  Apr 22, 2007
BioWorld Online,Hepsera (adefovir dipivoxil), for chronic hepatitis B, and AmBisome (amphotericin B), the liposome-for-injection therapy for severe fungal infections,

Gilead Sciences Announces First Quarter 2007 Financial Results  -  Apr 19, 2007
PharmaLive.com (press release),Hepsera(R) (adefovir dipivoxil) and AmBisome(R) (amphotericin B) liposome for injection also experienced solid sales growth compared to the same quarter

Fresh from the Pipeline: Telbivudine  -  Apr 5, 2007
Nature.com (subscription),It has since been joined on the market by the nucleotide analogue adefovir dipivoxil (Hepsera; Gilead) and the nucleoside analogues entecavir (Baraclude;

Gilead Sciences: Rapid Growth Expected From New Products  -  Apr 3, 2007
Seeking Alpha,...of Truvada (emtricitabine and tenofovir disoproxil fumarate) and Viread (tenofovir disoproxil fumarate), as well as Hepsera (adefovir dipivoxil).

BC likened to US after refusal to pay for costly treatment  -  Mar 22, 2007
Globe and Mail,About 350 BC residents are currently receiving Adefovir dipivoxil, marketed as Hepsera, for free, but those giveaways will come to an end by July.

Refusal to pay for drug sparks outrage in BC  -  Mar 21, 2007
Globe and Mail,Adefovir dipivoxil, marketed as Hepsera, costs about five times more than a drug approved by the provincial pharmacare program, but it is far more effective

Long-term adefovir therapy useful for chronic hepatitis B  -  Jan 30, 2007
Therapeutics Daily (subscription) (press release),NEW YORK (Reuters Health) - Treatment with adefovir dipivoxil for up to 5 years is well tolerated and provides a variety of benefits for patients with

Gilead Sciences Announces Fourth Quarter and Full Year 2006 ...  -  Feb 1, 2007
PharmaLive.com (press release),Truvada(R) (emtricitabine and tenofovir disoproxil fumarate) and Viread(R) (tenofovir disoproxil fumarate), as well as Hepsera(R) (adefovir dipivoxil).

Gilead Sciences Announces Fourth Quarter and Full Year 2006 ...  -  Jan 31, 2007
Business Wire (press release),...of Truvada ® (emtricitabine and tenofovir disoproxil fumarate) and Viread ® (tenofovir disoproxil fumarate), as well as Hepsera ® (adefovir dipivoxil).

Clinical Advances in Hepatitis B and Hepatitis C  -  Dec 6, 2006
Medscape (subscription)A multicenter Italian study of rescue adefovir dipivoxil therapy in lamivudine resistant patients: a 2-year analysis of 604 patients. Hepatology.

Adefovir Dipivoxil Increases Lasting Seroconversion in the ...  Nov 3, 2006
...positive chronic hepatitis B virus (HBV), 91% experienced lasting seroconversion of HBeAg after a median of 5 years of treatment with adefovir dipivoxil (10 mg ... -DG News Long-Term Treatment of HBeAg-positive Chronic Hepatitis B Patients ...  Nov 1, 2006
...e antigen (HBeAg)-positive experienced significant virological and biochemical responses to long-term treatment with adefovir dipivoxil, researchers reported ... -DG News Gilead Sciences Announces Third Quarter 2006 Financial Results  Oct 18, 2006
...tenofovir disoproxil fumarate 300 mg) following its US launch in July of this year, as well as continued solid product sales of Hepsera(R) (adefovir dipivoxil ... -Genetic Engineering News (press release), Clinical Advances in Hepatitis B and Hepatitis C  -  Dec 6, 2006
Medscape (subscription)A multicenter Italian study of rescue adefovir dipivoxil therapy in lamivudine resistant patients: a 2-year analysis of 604 patients. Hepatology.

Gilead Sciences Announces Second Quarter 2006 Financial Results  Jul 20, 2006
...robust performance of Truvada(R) (emtricitabine and tenofovir disoproxil fumarate), as well as continued strong product sales for Hepsera(R) (adefovir dipivoxil ... -Genetic Engineering News

Zoek in het archief  Jul 13, 2006
...of CMV retinitis in AIDS patients, Viread(R) (tenofovir disoproxil fumarate) for the treatment of HIV infection and Hepsera(R) (adefovir dipivoxil) for the ... -Netherlands Corporate News (persbericht)

Gilead Sciences and the IOCB Establish Academic Research Centre in ...  Jul 14, 2006
...of CMV retinitis in AIDS patients, Viread ® (tenofovir disoproxil fumarate) for the treatment of HIV infection and Hepsera ® (adefovir dipivoxil) for the ... -CombiChem.net (subscription)



Adefovir Dipivoxil Thwarts Recurrent Hepatitis B Virus Graft ...  Apr 27, 2006
VIENNA, AUSTRIA -- April 27, 2006 -- The combination of adefovir dipivoxil (ADV, Hepsera R ) and lamivudine started before liver transplantation and continued ... - DG News

Adefovir Dipivoxil Provides Effective Prophylaxis Against ...  Apr 28, 2006
New results document the safety and efficacy of the nucleotide analogue adefovir dipivoxil (ADV, HepseraR) for the prevention of graft re-infection in patients ... - Medical News Today

Independent Nurse: Clinical - Hepatitis B  May 10, 2006
...gives passive protection. - Current pharmacological options include interferon-alfa, lamivudine and adefovir dipivoxil. Hepatitis B ... - Therapeutics Daily (subscription)

Increasing Drug Resistance to Widely Used Treatment for Hepatitis ...  May 8, 2006
...report entitled Hepatitis B Virus finds that the uptake of Bristol-Myers Squibb's Baraclude (entecavir), Gilead's Hepsera (adefovir dipivoxil), and Novartis ... - PR Newswire

ΞΕÎ?Η ΔΗΜΟΣΙΕΥΣΗ-ΑÎ?ΑΚΟΙÎ?ΩΣΗ ΤΥΠΟΥ-PRN ...  Apr 27, 2006
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352(26):2673-81. [vii] Leung NW, Lai CL, Chang TT, et al. ... - Αθηναικο ΠÏ?ακτοÏ?είο Ειδήσεων

Gilead Sciences Announces First Quarter 2006 Financial Results  Apr 18, 2006
...and tenofovir disoproxil fumarate) and Viread(R) (tenofovir disoproxil fumarate), as well as continued strong product sales for Hepsera(R) (adefovir dipivoxil ... - Genetic Engineering News

The Navicor Group Named Agency of Record for Gilead's Hepsera  Apr 24, 2006
...agency that focuses exclusively in the areas of oncology and immunology, has been named agency of record for Hepsera(r) (adefovir dipivoxil), an orally ... - PharmaLive.com





Hepatitis B - Metabasis Comments On Positive 48 Week HBV Data From ...  Mar 16, 2006
...hepatitis B viral (HBV) DNA, a measure of viral load, from baseline as compared to a 4.19 log(10) drop in the 10 mg (QD) Hepsera (adefovir dipivoxil) group (p ... - Medical News Today

Valeant Pharmaceuticals Reports Positive Data from Pradefovir ...  Mar 16, 2006
The Phase 2 study consisted of five treatment groups: pradefovir - 5, 10, 20 and 30 mg/day (QD), and Hepsera (adefovir dipivoxil) - 10 mg/day (QD), with an ... - Genetic Engineering News

DNA-based test to detect hepa B, liver ailments  Mar 7, 2006
Oral meds like lamibudin, adefovir dipivoxil, entecavir, that cost P150 up to P300 per tablet can be taken for one year or maybe indefinite treatment depending ... - Journal Online

Healthcare: At a Glance - Roche Hepatitis Drug Thrust Onto Front ...  Mar 3, 2006
As well as making Pegasys a frontline drug, NICE has recommended Gilead Sciences' Hepsera (adefovir dipivoxil), which slows the progression of CHB, as a ... - International News Service,

Novartis/Idenix: Entering Hepatitis B Market  Feb 9, 2006
...telbivudine as none of the three antiviral therapies already available, namely GlaxoSmithKline's Zeffix, Gilead's Hepsera (adefovir dipivoxil) and Bristol ... - International News Service,

Novartis/Idenix: entering hepatitis B market  Feb 7, 2006
...telbivudine as none of the three antiviral therapies already available, namely GlaxoSmithKline's Zeffix, Gilead's Hepsera (adefovir dipivoxil) and Bristol ... - Pharmaceutical Business Review

Gilead Sciences Announces Fourth Quarter and Full Year 2005 ...  Jan 30, 2006
...launch in August of 2004, as well as continued strong product sales for AmBisome(R) (amphotericin B) liposome for injection and Hepsera(R) (adefovir dipivoxil ... - Genetic Engineering News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional